^
Association details:
| Biomarker: | PDGFRB C843G |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia
Excerpt:
...genomic profiling of longitudinally collected samples during treatment revealed the emergence of a mutation, PDGFRBC843G, which directly conferred resistance to all generations of ABL TKIs, including imatinib, dasatinib, nilotinib, and ponatinib.
DOI:
10.1182/blood-2017-11-817514
